natgillin/translations-raw huggingface dataset:
En indsamling, der svarer til et antal CD34+-reservestamceller på mindst 1,5 × 106 CD34+-celler/kg (hvis de indsamles ved aferese) eller &gt; 1,0 × 108 totalt antal kerneholdige celler (Total Nucleated Cell count, TNC)/kg (hvis de indsamles ved knoglemarvshøst), er påkrævet.
A back-up collection of CD34+ stem cells of at least 1.5 × 106 CD34+ cells/kg (if collected by apheresis) or &gt; 1.0 × 108 TNC/kg (if collected by bone marrow harvest) is required.
Yderligere oplysninger om dette lægemiddel findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu &lt; og på Lægemiddelstyrelsens hjemmeside http://www.laegemiddelstyrelsen.dk &gt; .
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu &lt; , and on the website of {name of MS Agency (link)} &gt; .
Infektioner og parasitÃ¦re sygdomme neutropen sepsis, systemisk infektion, stafylokokinfektion, pneumoni, infektion i de nedre luftveje, urinvejsinfektion, slimhindeinfektion, cellulitis, vaginal infektion, pustulÃ¸st udslÃ¦t, folliculitis, gingivitis
Neutropenic sepsis, Systemic infection, Staphylococcal infection, Pneumonia, Lower respiratory tract infection, Urinary tract infection, Mucosal infection, Cellulitis, Vaginal infection, Rash pustular, Folliculitis, Gingivitis
Almindelig (≥ 1 % - &lt; 10 %) hypokaliæmi, metabolisk acidose, overhydrering væskeretention, hypomagnesiæmi, hyponatriæmi, hypofosfatæmi
Hypocalcaemia, Hypokalaemia, Metabolic acidosis, Fluid overload, Fluid retention, Hypomagnesaemia, Hyponatraemia, Hypophosphataemia
Influenza A/eq/Ohio/03 [H3N8] rekombinant canarypox virus (vCP2242) ..............â¥ 5,3 log10 FAID50* Influenza A/eq/Richmond/1/07 [H3N8] rekombinant canarypox virus (vCP3011) ...................................................................................................................................â¥ 5,3 log10 FAID50* * vCP indhold kontrolleret ved global FAID50 (fluorescent assay" infektiÃ¸s dosis 50 %) og qPCR rate mellem vCP.
Influenza A/eq/Ohio/03 [H3N8] recombinant canarypox virus (vCP2242) ............. â¥ 5.3 log10 FAID50* Influenza A/eq/Richmond/1/07 [H3N8] recombinant canarypox virus (vCP3011) .. â¥ 5.3 log10 FAID50*
Meget almindelig ( &gt; 1/10); almindelig ( &gt; 1/100, &lt; 1/10); ualmindelig ( &gt; 1/1000, &lt; 1/100); sjælden ( &gt; 1/10000, &lt; 1/1000); meget sjælden ( &lt; 1/10000), inklusive isolerede tilfælde.
Very common ( &gt; 1/10); common ( &gt; 1/100, &lt; 1/10); uncommon ( &gt; 1/1000, &lt; 1/100); rare ( &gt; 1/10000, &lt; 1/1000); very rare ( &lt; 1/10000), including isolated reports.
Det anbefales, at &lt; COVERSYL og øvrige navne &gt; tages én gang dagligt om morgenen før et måltid.
It is recommended that &lt; COVERSYL and associated names &gt; is taken once daily in the morning before a meal.
Hæmodialysepatienter * ClKR &lt; 15
Haemodialysed patients * ClCR &lt; 15
I sådanne tilfælde skal &lt; COVERSYL og øvrige navne &gt; seponeres omgående, og passende observation skal initieres og fortsættes, indtil symptomerne er svundet fuldstændig.
In such cases, &lt; COVERSYL and associated names &gt; should promptly be discontinued and appropriate monitoring should be initiated and continued until complete resolution of symptoms has occurred.
Graviditet &lt; COVERSYL og øvrige navne &gt; må ikke bruges under første trimester af graviditeten.
Pregnancy: &lt; COVERSYL and associated names &gt; should not be used during the first trimester of pregnancy.
Efterfølgende dosering af &lt; COVERSYL og øvrige navne &gt; skal justeres efter blodtryksreaktion.
The subsequent dosage of &lt; COVERSYL and associated names &gt; should be adjusted according to blood pressure response.
LÆGEMIDLETS NAVN &lt; COVERSYL og øvrige navne (se bilag I) &gt; , &lt; styrke &gt; , tabletter &lt; [Se bilag I - Udfyldes nationalt] &gt;
NAME OF THE MEDICINAL PRODUCT &lt; COVERSYL and associated names (see Annex I) &gt; , &lt; strength &gt; , tablets &lt; [See Annex I - to be completed nationally] &gt;
I komparative studier er den første dosis af 2 mg &lt; COVERSYL og øvrige navne &gt; hos patienter med mild til moderat hjerteinsufficiens ikke sat i forbindelse med nogen væsentlig nedsættelse af blodtrykket sammenlignet med placebo.
In comparative studies, the first administration of 2 mg of &lt; COVERSYL and associated names &gt; to patients with mild to moderate heart failure was not associated with any significant reduction of blood pressure as compared to placebo.
Det anbefales, at behandlingen med &lt; COVERSYL og øvrige navne &gt; , der normalt sker i forbindelse med et ikke kaliumbesparende diuretikum og/eller digoxin og/eller en betablokker, indledes under tæt lægeligt opsyn med en anbefalet startdosis på 2 mg, der tages om morgenen.
It is recommended that &lt; COVERSYL and associated names &gt; , generally associated with a nonpotassium-sparing diuretic and/or digoxin and/or a beta blocker, be introduced under close medical supervision with a recommended starting dose of 2 mg taken in the morning.
Eftersom indtagelse af føde nedsætter omdannelsen af perindoprilat og dermed biotilgængeligheden, skal &lt; COVERSYL og øvrige navne &gt; indgives oralt i en enkelt daglig dosis om morgenen før et måltid.
As ingestion of food decreases conversion to perindoprilat, hence bioavailability, &lt; COVERSYL and associated names &gt; should be administered orally in a single daily dose in the morning before a meal.
Der er ingen erfaringer med hensyn til behandling med &lt; COVERSYL og øvrige navne &gt; hos patienter, som for nylig har fået foretaget nyretransplantation.
There is no experience regarding the administration of &lt; COVERSYL and associated names &gt; in patients with a recent kidney transplantation.
Eftersom behandling med diuretika kan være en medvirkende faktor ved ovennævnte, skal en sådan behandling seponeres, og nyrefunktionen skal overvåges under de første ugers behandling med &lt; COVERSYL og øvrige navne &gt; .
Since treatment with diuretics may be a contributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of &lt; COVERSYL and associated names &gt; therapy.
Hos nogle patienter med kongestiv hjerteinsufficiens, hvis blodtryk er normalt eller lavt, kan der forekomme yderligere nedsættelse af det systemiske blodtryk ved behandling med &lt; COVERSYL og øvrige navne &gt; .
In some patients with congestive heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with &lt; COVERSYL and associated names &gt; .
Hypertension &lt; COVERSYL og øvrige navne &gt; kan bruges som monoterapi eller i kombination med andre former for behandling mod hypertension
Hypertension: &lt; COVERSYL and associated names &gt; may be used in monotherapy or in combination with other classes of antihypertensive therapy.
I tilfælde af nedsat nyrefunktion (kreatininclearance &lt; 60 ml/min) skal startdosis af perindopril justeres efter patientens kreatininclearance (se 4.2 ”Dosering og indgivelsesmåde”) og derpå efter patientens respons på behandlingen.
In cases of renal impairment (creatinine clearance &lt; 60 ml/min) the initial perindopril dosage should be adjusted according to the patient's creatinine clearance (see 4.2 “Posology and method of administration”) and then as a function of the patient's response to treatment.
Behandlingen med perindopril 8 mg en gang daglig resulterede i en signifikant absolut reduktion i det primære endepunkt på 1,9% (relativ risikoreduktion på 20% (95% CI [9,4; 28,6] - p &lt; 0,001).
The treatment with perindopril 8 mg once daily resulted in a significant absolute reduction in the primary endpoint of 1.9% (relative risk reduction of 20%, 95%CI [9.4; 28.6] - p &lt; 0.001).
Hjerteinsufficiens &lt; COVERSYL og øvrige navne &gt; reducerer hjertearbejdet gennem reduceret for- og efterbelastning.
Heart failure: &lt; COVERSYL and associated names &gt; reduces cardiac work by a decrease in pre-load and after-load.
15 &lt; ClKR &lt; 30
15 &lt; ClCR &lt; 30
Hvis det er muligt, bør den diuretiske behandling seponeres 2 til 3 dage, før behandlingen med &lt; COVERSYL og øvrige navne &gt; indledes (se afsnit 4.4 ”Særlige advarsler og forsigtighedsregler vedrørende brugen”).
If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with &lt; COVERSYL and associated names &gt; (see section 4.4 “Special warnings and special precautions for use”).
Hvis hypotensionen bliver symptomatisk, kan det være nødvendigt at reducere dosis eller seponere behandlingen med &lt; COVERSYL og øvrige navne &gt; .
If hypotension becomes symptomatic, a reduction of dose or discontinuation of &lt; COVERSYL and associated names &gt; may be necessary.
Patienter med høj risiko for symptomatisk hypotension, fx patienter, der er saltdepleterede med eller uden hyponatriæmi, patienter med hypovolæmi eller patienter, der har modtaget kraftig diuretikabehandling, skal så vidt muligt have disse tilstande korrigeret før behandling med &lt; COVERSYL og øvrige navne &gt; .
Patients at high risk of symptomatic hypotension e.g. patients with salt depletion with or without hyponatraemia, patients with hypovolaemia or patients who have been receiving vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy with &lt; COVERSYL and associated names &gt; .
30 &lt; ClKR &lt; 60
30 &lt; ClCR &lt; 60
Dosisreduktion og/eller seponering af den diuretiske behandling og/eller COVERSYL kan være påkrævet.
Dosage reduction and/or discontinuation of the diuretic and/or &lt; COVERSYL and associated names &gt; may be required.
Blodtryk, nyrefunktion og serumkalium skal nøje overvåges, både før og under behandling med &lt; COVERSYL og øvrige navne &gt; (se afsnit 4.4 ”Særlige advarsler og forsigtighedsregler vedrørende brugen”).
Blood pressure, renal function and serum potassium should be monitored closely, both before and during treatment with &lt; COVERSYL and associated names &gt; (see section 4.4 “Special warnings and special precautions for use”).
Derfor frarådes brugen af &lt; COVERSYL og øvrige navne &gt; til kvinder, der ammer.
Therefore the use of &lt; COVERSYL and associated names &gt; is not recommended in women who are breast-feeding.
INDEHAVER AF MARKEDSFØRINGSTILLADELSEN &lt; [Se bilag I - Udfyldes nationalt] &gt;
MARKETING AUTHORISATION HOLDER &lt; [See Annex I- to be completed nationally] &gt;
&lt; COVERSYL og øvrige navne &gt; 2 mg: 2 mg perindopril tertiært butylaminsalt svarende til 1,669 mg perindopril
&lt; COVERSYL and associated names &gt; 2 mg: 2 mg perindopril tert-butylamine salt, equivalent to 1.669 mg perindopril
&lt; COVERSYL og øvrige navne) &gt; 4 mg: 4 mg perindopril tertiært butylaminsalt svarende til 3,338 mg perindopril
&lt; COVERSYL and associated names &gt; 4 mg: 4 mg perindopril tert-butylamine salt, equivalent to 3.338 mg perindopril
2 mg perindopril tertiært butylaminsalt svarende til 1,669 mg perindopril &lt; [Udfyldes nationalt] &gt;
2 mg perindopril tert-butylamine salt, equivalent to 1.669 mg perindopril &lt; [To be completed nationally] &gt;
Hos hypertensive patienter, hvor den diuretiske behandling ikke kan seponeres, bør behandlingen med &lt; COVERSYL og øvrige navne &gt; indledes med en dosis på 2 mg. Nyrefunktion og serumkalium skal overvåges.
In hypertensive patients in whom the diuretic cannot be discontinued, therapy with &lt; COVERSYL and associated names &gt; should be initiated with a 2 mg dose.
Nogle hypertensive patienter uden kendte tidligere nyrekarsygdomme har udviklet øgede mængder urinstof i blodet og forhøjet serumkreatinin, sædvanligvis i mild og forbigående grad, særligt når COVERSYL er givet samtidig med et diuretikum.
Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when &lt; COVERSYL and associated names &gt; has been given concomitantly with a diuretic.
4 mg perindopril tertiært butylaminsalt svarende til 3,338 mg perindopril &lt; [Udfyldes nationalt] &gt;
4 mg perindopril tert-butylamine salt, equivalent to 3.338 mg perindopril &lt; [To be completed nationally] &gt;
Angioødem i ansigt, ekstremiteter, læber, slimhinder, tunge, glottis og/eller larynx er i sjældne tilfælde rapporteret hos patienter i behandling med ACE-hæmmere, inklusive &lt; COVERSYL og øvrige navne &gt; (se 4.8 Bivirkninger).
Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/or larynx has been reported rarely in patients treated with ACE inhibitors, including &lt; COVERSYL and associated names &gt; (see 4.8 Undesirable effects).
Hos patienter med tidligere myokardieinfarkt og/eller revaskularisering, observeredes en absolut reduktion på 2,2% svarende til en RRRpå 22,4% (95% CI [12,0; 31,6] - p &lt; 0,001) i det primære endepunkt sammenlignet med placebo.
In patients with a history of myocardial infarction and/or revascularisation, an absolute reduction of 2.2% corresponding to a RRR of 22.4% (95%CI [12.0; 31.6] - p &lt; 0.001) in the primary endpoint was observed by comparison to placebo.
Aorta- og mitralklapstenose/hypertrofisk kardiomyopati Som ved alle andre ACE-hæmmere bør &lt; COVERSYL og øvrige navne &gt; gives med forsigtighed til patienter med mitralklapstenose og obstrueret outflow fra venstre ventrikel, som fx aortastenose eller hypertrofisk kardiomypati.
As with other ACE inhibitors, &lt; COVERSYL and associated names &gt; should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.
Behandling med &lt; COVERSYL and associated names &gt; skal indledes med en dosis på 4 mg en gang daglig i to uger, hvorefter dosis øges til 8 mg en gang daglig afhængigt af nyrefunktionen og forudsat, at en dosis på 4 mg er veltolereret.
Stable coronary artery disease: &lt; COVERSYL and associated names &gt; should be introduced at a dose of 4 mg once daily for two weeks, then increased to 8 mg once daily, depending on renal function and provided that the 4 mg dose is well tolerated.
FARMACEUTISKE OPLYSNINGER 6.1 Fortegnelse over hjælpestoffer &lt; [Udfyldes nationalt] &gt;
PHARMACEUTICAL PARTICULARS 6.1 List of excipients &lt; [To be completed nationally] &gt; 6.2 Incompatibilities &lt; [To be completed nationally] &gt;
6.6 Eventuelle instruktioner vedrørende anvendelse og håndtering &lt; [Udfyldes nationalt] &gt;
6.4 Special precautions for storage &lt; [To be completed nationally] &gt; 6.6 Nature and contents of container &lt; [To be completed nationally] &gt; 6.6 Instructions for use and handling &lt; and disposal &gt; &lt; [To be completed nationally] &gt;
Kirurgi/anæstesi &lt; COVERSYL og øvrige navne &gt; kan blokere angiotensin II-dannelsen sekundært til kompenserende reninafgivelse hos patienter, som får foretaget større operationer eller under anæstesi med midler, som giver hypotension.
In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, &lt; COVERSYL and associated names &gt; may block angiotensin II formation secondary to compensatory renin release.
Symptomatisk hypotension kan forekomme efter indledning af behandlingen med &lt; COVERSYL og øvrige navne &gt; .
Symptomatic hypotension may occur following initiation of therapy with &lt; COVERSYL and associated names &gt; ; this is more likely in patients who are being treated concurrently with diuretics.
6.5 Emballage (art og indhold) &lt; [Udfyldes nationalt] &gt;
6.3 Shelf life &lt; [To be completed nationally] &gt; 6.4 Special precautions for storage &lt; [To be completed nationally] &gt; 6.5 Nature and contents of container &lt; [To be completed nationally] &gt; 6.6 Instructions for use and handling &lt; and disposal &gt; &lt; [To be completed nationally] &gt;
Hyppigheden defineres som meget almindelig (≥ 1/10), almindelig (≥ 1/100 til &lt; 1/10), ikke almindelig (≥ 1/1 000 til &lt; 1/100), sjælden (≥ 1/10 000 til &lt; 1/1 000), meget sjælden ( &lt; 1/10 000) eller ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Forskellen i clearance mellem Fabry-patienter over 65 og under 65 år var 20 %, hvilket ikke blev anset for at have klinisk betydning.
The difference in clearance between Fabry patients ≥ 65 years and those &lt; 65 years was 20%, which was not considered clinically significant.
I de kliniske studier med Galafold indgik et lille antal patienter over 65 år.
Elderly ( &gt; 65 years) Clinical studies of Galafold included small number of patients aged 65 and over.
I forsøget med ERT-erfarne patienter var der efter 18 måneders behandling med Galafold en statistisk signifikant mindskelse i LVMi (p &lt; 0,05).
In the ERT-experienced trial, following 18 months of treatment with Galafold there was a statistically significant decrease in LVMi (p &lt; 0.05).
UKENDT IVS6-10G &gt; A; IVS6-22C &gt; T c.1000-10G &gt; A/1000-22C &gt; T UKENDT
UNKNOWN IVS6-10G &gt; A; IVS6-22C &gt; T c.1000-10G &gt; A/1000-22C &gt; T UNKNOWN
Patientrapporterede resultater - skala for vurdering af gastrointestinale symptomer I forsøget med ERT-naive patienter viste analyser af skalaen for vurdering af gastrointestinale symptomer, at fra baseline til måned 6 var behandling med Galafold forbundet med statistisk signifikant bedring af diarré og refluks i forhold til placebo (p &lt; 0,05) for patienter med symptomer ved baseline.
Patient-Reported Outcome - Gastrointestinal Symptoms Rating Scale In the ERT-naïve trial, analyses of the Gastrointestinal Symptoms Rating Scale demonstrated that treatment with Galafold was associated with statistically significant (p &lt; 0.05) improvements versus placebo from baseline to month 6 in the diarrhoea domain, and in the reflux domain for patients with symptoms at baseline.
I den åbne forlængelsesperiode sås statistisk signifikant (p &lt; 0,05) bedring fra baseline af diarré og fordøjelsesbesvær og en tendens til bedring af obstipation.
During the open-label extension, statistically significant (p &lt; 0.05) improvements from baseline were observed in the diarrhoea and indigestion domains, with a trend of improvement in the constipation domain.
Ændring i proteinsekvens c.1A &gt; C eller c.1A &gt; T
Protein Sequence change c.1A &gt; C or c.1A &gt; T
c.1018T &gt; C eller c.1018T &gt; A c.T1018C eller c.T1018A
c.1018T &gt; C or c.1018T &gt; A c.T1018C or c.T1018A
c.140G &gt; A eller 141G &gt; A
c.140G &gt; A or 141G &gt; A
I forsøget med ERT-naive patienter medførte Galafold en statistisk signifikant mindskelse i LVMi (p &lt; 0,05); den gennemsnitlige ændring fra baseline i LVMi ved måned 18 til 24 var -7,7 (95 % CI:-15,4; -0,01; n=27).
In the ERT-naïve trial, Galafold resulted in a statistically significant decrease in LVMi (p &lt; 0.05); the mean change from baseline in LVMi at Month 18 to 24 was -7.7 (95% CI: -15.4, -0.01; n=27).
c.611G &gt; A eller 612G &gt; A
c.611G &gt; A or 612G &gt; A
c.712A &gt; C eller c.714T &gt; A eller c.714T &gt; G
c.712A &gt; C or c.714T &gt; A or c.714T &gt; G
g.10237_11932del/11933_12083i nv/12084_12097del g. &gt; 5.5kbdel tis 3UTR
g.10237_11932del/11933_12083i nv/12084_12097del
c.442A &gt; C eller c.444T &gt; A eller c.444T &gt; G
c.442A &gt; C or c.444T &gt; A or c.444T &gt; G
c.504A &gt; C eller c.504A &gt; T
c.504A &gt; C or c.504A &gt; T
c.924A &gt; T eller c.924A &gt; C
c.924A &gt; T or c.924A &gt; C
Gennemsnitsændringen fra baseline i LVMi ved måned 18 til 24 hos patienter med hypertrofi af venstre ventrikel ved baseline (baseline-LVMi &gt; 95 g/m2 for kvinder og baseline-LVMi &gt; 115 g/m for mænd) var -18,6 (95 % CI: -38,2; 1,0; n=8).
The mean change from baseline in LVMi at Month 18 to 24 in patients with left ventricular hypertrophy at baseline (females with baseline LVMi &gt; 95 g/m or males with baseline LVMi &gt; 115 g/m 2) was -18.6 (95% CI: -38.2, 1.0; n=8).
c.1147T &gt; C eller c.1149C &gt; G eller c.1149C &gt; A
c.1147T &gt; C or c.1149C &gt; G or c.1149C &gt; A
c.561G &gt; T eller c.561G &gt; A eller c.561G &gt; C
c.561G &gt; T or c.561G &gt; A or c.561G &gt; C
c.70T &gt; C eller c.70T &gt; A
c.70T &gt; C or c.70T &gt; A
c.280T &gt; A eller c.281G &gt; C
c.280T &gt; A or c.281G &gt; C
c.1045T &gt; C eller c.1045T &gt; A c.T1045C eller c.T1045A
c.1045T &gt; C or c.1045T &gt; A c.T1045C or c.T1045A
c.1095T &gt; A eller c.1095T &gt; G c.T1095A eller c.T1095G
c.1095T &gt; A or c.1095T &gt; G c.T1095A or c.T1095G
c.216G &gt; A eller c.216G &gt; T eller c.216G &gt; C
c.216G &gt; A or c.216G &gt; T or c.216G &gt; C
c.817T &gt; C eller c.819T &gt; A eller c.819T &gt; G
c.817T &gt; C or c.819T &gt; A or c.819T &gt; G
c.337T &gt; C eller c.339T &gt; A eller c.339T &gt; G
c.337T &gt; C or c.339T &gt; A or c.339T &gt; G
c.412G &gt; A eller c.412G &gt; C
c.412G &gt; A or c.412G &gt; C
c.71G &gt; A eller c.72G &gt; A
c.71G &gt; A or c.72G &gt; A
c.982G &gt; A eller c.982G &gt; C
c.982G &gt; A or c.982G &gt; C
c.228G &gt; C eller c.228G &gt; A eller c.228G &gt; T
c.228G &gt; C or c.228G &gt; A or c.228G &gt; T
c.612G &gt; T eller c.612G &gt; C
c.612G &gt; T or c.612G &gt; C
c.187T &gt; A eller c.188G &gt; C
c.187T &gt; A or c.188G &gt; C
c.261G &gt; C eller c.261G &gt; T
c.261G &gt; C or c.261G &gt; T
c.124A &gt; C eller c.124A &gt; T
c.124A &gt; C or c.124A &gt; T
c.285G &gt; T eller c.285G &gt; C
c.285G &gt; T or c.285G &gt; C
c.471G &gt; C eller c.471G &gt; T
c.471G &gt; C or c.471G &gt; T
c.166T &gt; A eller c.167G &gt; C
c.166T &gt; A or c.167G &gt; C
c.609G &gt; C eller c.609G &gt; T
c.609G &gt; C or c.609G &gt; T
c.243G &gt; T eller c.243G &gt; C
c.243G &gt; T or c.243G &gt; C
c.132G &gt; T eller c.132G &gt; C
c.132G &gt; T or c.132G &gt; C
c.144G &gt; T eller c.144G &gt; C
c.144G &gt; T or c.144G &gt; C
c.540G &gt; C eller c.540G &gt; T
c.540G &gt; C or c.540G &gt; T
c.567G &gt; C eller c.567G &gt; T
c.567G &gt; C or c.567G &gt; T
c.108G &gt; C eller c.108G &gt; T
c.108G &gt; C or c.108G &gt; T
c.141G &gt; C eller c.141G &gt; T
c.141G &gt; C or c.141G &gt; T
c.831G &gt; T eller c.831G &gt; C
c.831G &gt; T or c.831G &gt; C
c.784T &gt; A eller c.784T &gt; C
c.784T &gt; A or c.784T &gt; C
W399S c.1202C &gt; G eller c.1202C &gt; A c.C1202G eller c.C1202A S401X c.1215T &gt; A
Protein Sequence change c.1202C &gt; G or c.1202C &gt; A c.C1202G or c.C1202A
c.154T &gt; A eller c.155G &gt; C
c.154T &gt; A or c.155G &gt; C
Patienter med nedsat nyrefunktion Galafold er ikke undersøgt hos Fabry-patienter med GFR under 30 ml/min/1,73 m2. I et enkeltdosisstudie med Galafold hos personer uden Fabrys sygdom, men med forskellige grader af nyreinsufficiens var eksponeringen øget med en faktor 4,3 hos personer med svært nedsat nyrefunktion (GFR &lt; 30 ml/min/1,73 m
In a single dose study with Galafold in non-Fabry subjects with varying degrees of renal insufficiency, exposures were increased by 4.3-fold in subjects with severe renal impairment (GFR &lt; 30 mL/min/1.73 m
c.963G &gt; C eller c.963G &gt; T
c.963G &gt; C or c.963G &gt; T
c.514T &gt; A eller c.515G &gt; C
c.514T &gt; A or c.515G &gt; C
c.439G &gt; A eller c.439G &gt; C
c.439G &gt; A or c.439G &gt; C
c.870G &gt; A eller c.870G &gt; C eller c.870G &gt; T
c.870G &gt; A or c.870G &gt; C or c.870G &gt; T
c.888G &gt; A eller c.888G &gt; T eller c.888G &gt; C
c.888G &gt; A or c.888G &gt; T or c.888G &gt; C
c.394G &gt; A eller c.394G &gt; C
c.394G &gt; A or c.394G &gt; C
c.708G &gt; C eller c.708G &gt; T
c.708G &gt; C or c.708G &gt; T
c.840A &gt; T eller c.840A &gt; C
c.840A &gt; T or c.840A &gt; C
c.588A &gt; T eller c.588A &gt; C
c.588A &gt; T or c.588A &gt; C
c.861G &gt; C eller c.861G &gt; T
c.861G &gt; C or c.861G &gt; T